Page 26 - TD-4-2

Tumor Discovery Melanoma exosomes in metastasis

squamous cell carcinoma, a malignant transformation of progression and metastasis. Nat Med. 2013;19:1423-1437.
actinic keratoses. Eur J Pharm Biopharm. 2012;81:102-112.
doi: 10.1038/nm.3394
doi: 10.1016/j.ejpb.2012.02.008
99. Ambrosini G, Rai AJ, Carvajal RD, Schwartz GK.
88. Shao J, Zaro J, Shen Y. Advances in exosome-based drug Uveal melanoma exosomes induce a prometastatic
delivery and tumor targeting: From tissue distribution to microenvironment through macrophage migration
intracellular fate. Int J Nanomed. 2020;15:9355-9371. inhibitory factor. Mol Cancer Res. 2022;20:661-669.
doi: 10.2147/ijn.S281890 doi: 10.1158/1541-7786.Mcr-21-0526
89. Horodecka K, Düchler M. CRISPR/Cas9: Principle, 100. Li J, Cai J, Zhao S, et al. GANT61, a GLI inhibitor, sensitizes
applications, and delivery through extracellular vesicles. Int glioma cells to the temozolomide treatment. J Exp Clin
J Mol Sci. 2021;22:6072. Cancer Res. 2016;35:184.
doi: 10.3390/ijms22116072 doi: 10.1186/s13046-016-0463-3
90. Shi A, Li J, Qiu X, et al. TGF-β loaded exosome enhances 101. Tan Y, Tang F, Li J, et al. Tumor-derived exosomes: The
ischemic wound healing in vitro and in vivo. Theranostics. emerging orchestrators in melanoma. Biomed Pharmacother.
2021;11:6616-6631. 2022;149:112832.
doi: 10.7150/thno.57701 doi: 10.1016/j.biopha.2022.112832
91. Poongodi R, Chen YL, Yang TH, et al. Bio-scaffolds as cell 102. Gyukity-Sebestyén E, Harmati M, Dobra G, et al. Melanoma-
or exosome carriers for nerve injury repair. Int J Mol Sci. derived exosomes induce PD-1 overexpression and
2021;22:13347. tumor progression via mesenchymal stem cell oncogenic
reprogramming. Front Immunol. 2019;10:2459.
doi: 10.3390/ijms222413347
doi: 10.3389/fimmu.2019.02459
92. Moghaddam AS, Afshari JT, Esmaeili SA, Saburi E,
Joneidi Z, Momtazi-Borojeni AA. Cardioprotective microRNAs: 103. Li T, Wu T, Li X, Qian C. Transcriptional switches in
Lessons from stem cell-derived exosomal microRNAs to treat melanoma T Cells: Facilitating polarizing into regulatory T
cardiovascular disease. Atherosclerosis. 2019;285:1-9. cells. Int Immunopharmacol. 2024;137:112484.
doi: 10.1016/j.atherosclerosis.2019.03.016 doi: 10.1016/j.intimp.2024.112484
93. Shen Z, Huang W, Liu J, Tian J, Wang S, Rui K. Effects of 104. Asleh K, Dery V, Taylor C, et al. Extracellular vesicle-based
mesenchymal stem cell-derived exosomes on autoimmune liquid biopsy biomarkers and their application in precision
diseases. Front Immunol. 2021;12:749192. immuno-oncology. Biomarker Res. 2023;11:99.
doi: 10.3389/fimmu.2021.749192 doi: 10.1186/s40364-023-00540-2
94. Yang B, Chen Y, Shi J. Exosome biochemistry and advanced 105. Pathania AS, Prathipati P, Challagundla KB. New insights
nanotechnology for next-generation theranostic platforms. into exosome mediated tumor-immune escape: Clinical
Adv Mater. 2019;31:e1802896. perspectives and therapeutic strategies. Biochim Biophys
Acta Rev Cancer. 2021;1876:188624.
doi: 10.1002/adma.201802896
doi: 10.1016/j.bbcan.2021.188624
95. Kim H, Kim H, Feng Y, et al. PRMT5 control of cGAS/
STING and NLRC5 pathways defines melanoma response 106. Petersen KE, Manangon E, Hood JL, et al. A review of
to antitumor immunity. Sci Transl Med. 2020;12:eaaz5683. exosome separation techniques and characterization of B16-
F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-
doi: 10.1126/scitranslmed.aaz5683
TEM. Anal Bioanal Chem. 2014;406:7855-7866.
96. Najem A, Soumoy L, Sabbah M, et al. Understanding doi: 10.1007/s00216-014-8040-0
molecular mechanisms of phenotype switching and crosstalk
with TME to reveal new vulnerabilities of melanoma. Cells. 107. Zhu L, Kalimuthu S, Gangadaran P, et al. Exosomes derived
2022;11:1157. from natural killer cells exert therapeutic effect in melanoma.
Theranostics. 2017;7:2732-2745.
doi: 10.3390/cells11071157
doi: 10.7150/thno.18752
97. Wei CY, Zhu MX, Yang YW, et al. Downregulation of
RNF128 activates Wnt/β-catenin signaling to induce cellular 108. Erman A, Ignjatović M, Leskovšek K, et al. The prognostic
EMT and stemness via CD44 and CTTN ubiquitination in and predictive value of human gastrointestinal microbiome
melanoma. J Hematol Oncol. 2019;12:21. and exosomal mRNA expression of PD-L1 and IFNγ for
immune checkpoint inhibitors response in metastatic
doi: 10.1186/s13045-019-0711-z
melanoma patients: PROTOCOL TRIAL. Biomedicines.
98. Quail DF, Joyce JA. Microenvironmental regulation of tumor 2023;11:2016.

Volume 4 Issue 2 (2025) 18 doi: 10.36922/td.7108